Alaa Alhazmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alaa Alhazmi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Fakhra Jabeen
Department of Physical Sciences, College of Science, Jazan University, Jazan, Saudi Arabia
1 shared publication - Kamal Upreti
Department of Computer Science, CHRIST (Deemed to be University), Delhi NCR, Ghaziabad, Uttar Pradesh, India
1 shared publication - Mohammad Mazharul Hoque
Department of Emergency Medicine, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia
1 shared publication - Mohammad Shane Alam
Department of Mathematics, Aligarh Muslim University, Aligarh 202002, India
1 shared publication - Mohammad Suhail Akhter
Department of Medical Laboratory Technology, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia
1 shared publication - Rituraj Jain
Chandigarh University, India
1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 2 (19) , 1595
Comparative Evaluation of Cardiovascular Biomarkers in Diabetic and Non-Diabetic Myocardial Infarction Patients in Saudi Arabia
This study discusses the effect of diabetes mellitus (DM) and the importance of biochemical markers in the timely diagnosis, management and prognostication of acute myocardial infarction (AMI) through the measurement of cardiac enzymes in diabetic and non-diabetic patients with AMI.A cohort of 300 individuals of ages of 55-80 years were selected for case control study. Three groups of participants were identified: normal (N), Diabetic Acute Myocardial Infarction (D-AMI), and Non-diabetic Acute Myocardial Infarction (ND-AMI).Each participant underwent a thorough history, medical evaluation, and assessment of cardiovascular parameters.These parameters included fasting blood glucose, glycated hemoglobin (HbA1c), systolic and diastolic blood pressure, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and the ratios of TC/HDL and LDL/HDL.The cardiac biomarkers measured included aspartate aminotransferase (AST), lactate dehydrogenase (LDH), C-reactive protein (CRP), creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), and troponin-I.While TC, TG, and LDL-C levels were high, HDL-C levels were considerably lower in the D-AMI group than in the N-AMI group. Irrespective of whether they had diabetes mellitus, the study's findings demonstrated that individuals with myocardial infarction had considerably higher rates of cardiac biomarkers, including troponin I, CPK, CK-MB, AST, LDH, and CRP.Research indicates that individuals with D-AMI have higher cardiac indicators than those with ND-AMI.
- 25 June 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 2 (19) , 1595
Open AccessComparative Evaluation of Cardiovascular Biomarkers in Diabetic and Non-Diabetic Myocardial Infarction Patients in Saudi Arabia
This study discusses the effect of diabetes mellitus (DM) and the importance of biochemical markers in the timely diagnosis, management and prognostication of acute myocardial infarction (AMI) through the measurement of cardiac enzymes in diabetic and non-diabetic patients with AMI.A cohort of 300 individuals of ages of 55-80 years were selected for case control study. Three groups of participants were identified: normal (N), Diabetic Acute Myocardial Infarction (D-AMI), and Non-diabetic Acute Myocardial Infarction (ND-AMI).Each participant underwent a thorough history, medical evaluation, and assessment of cardiovascular parameters.These parameters included fasting blood glucose, glycated hemoglobin (HbA1c), systolic and diastolic blood pressure, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and the ratios of TC/HDL and LDL/HDL.The cardiac biomarkers measured included aspartate aminotransferase (AST), lactate dehydrogenase (LDH), C-reactive protein (CRP), creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), and troponin-I.While TC, TG, and LDL-C levels were high, HDL-C levels were considerably lower in the D-AMI group than in the N-AMI group. Irrespective of whether they had diabetes mellitus, the study's findings demonstrated that individuals with myocardial infarction had considerably higher rates of cardiac biomarkers, including troponin I, CPK, CK-MB, AST, LDH, and CRP.Research indicates that individuals with D-AMI have higher cardiac indicators than those with ND-AMI.
- 20 June 2018
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 10 (4) , 255-263
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection
Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine kinase which associates directly with extracellular receptors, and is critically involved in signal transduction pathways in a variety of cell types for the regulation of cellular responses. SYK is expressed ubiquitously in immune and nonimmune cells, and has a much wider biological role than previously recognized. Several studies have highlighted SYK as a key player in the pathogenesis of a multitude of diseases. Pseudomonas aeruginosa is an opportunistic gram-negative pathogen, which is responsible for systemic infections in immunocompromised individuals, accounting for a major cause of severe chronic lung infection in cystic fibrosis patients and subsequently resulting in a progressive deterioration of lung function. Inhibition of SYK activity has been explored as a therapeutic option in several allergic disorders, autoimmune diseases, and hematological malignancies. This review focuses on SYK as a therapeutic target, and describes the possibility of how current knowledge could be translated for therapeutic purposes to regulate the immune response to the opportunistic pathogen P. aeruginosa.
- 20 June 2018
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 10 (4) , 255-263
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection
Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine kinase which associates directly with extracellular receptors, and is critically involved in signal transduction pathways in a variety of cell types for the regulation of cellular responses. SYK is expressed ubiquitously in immune and nonimmune cells, and has a much wider biological role than previously recognized. Several studies have highlighted SYK as a key player in the pathogenesis of a multitude of diseases. Pseudomonas aeruginosa is an opportunistic gram-negative pathogen, which is responsible for systemic infections in immunocompromised individuals, accounting for a major cause of severe chronic lung infection in cystic fibrosis patients and subsequently resulting in a progressive deterioration of lung function. Inhibition of SYK activity has been explored as a therapeutic option in several allergic disorders, autoimmune diseases, and hematological malignancies. This review focuses on SYK as a therapeutic target, and describes the possibility of how current knowledge could be translated for therapeutic purposes to regulate the immune response to the opportunistic pathogen P. aeruginosa.
- 20 January 2018
- Published by Springer Nature in Inflammation Research
- Vol. 67 (6) , 479-493
NOD-like receptor(s) and host immune responses with Pseudomonas aeruginosa infection
Molecular mechanisms underlying the interactions between Pseudomonas aeruginosa, the common opportunistic pathogen in cystic fibrosis individuals, and host induce a number of marked inflammatory responses and associate with complex therapeutic problems due to bacterial resistance to antibiotics in chronic stage of infection.
- 20 January 2018
- Published by Springer Nature in Inflammation Research
- Vol. 67 (6) , 479-493
NOD-like receptor(s) and host immune responses with Pseudomonas aeruginosa infection
Molecular mechanisms underlying the interactions between Pseudomonas aeruginosa, the common opportunistic pathogen in cystic fibrosis individuals, and host induce a number of marked inflammatory responses and associate with complex therapeutic problems due to bacterial resistance to antibiotics in chronic stage of infection.
- Open Access
- 8 January 2015
- Published by Canadian Center of Science and Education in International Journal of Biology
- Vol. 7 (2) , p44
Pseudomonas aeruginosa – Pathogenesis and Pathogenic Mechanisms
Pseudomonas aeruginosa is a common bacterium, Gram-negative opportunistic pathogen capable of infecting humans with compromised natural defenses and causing severe pulmonary disease. It is one of the leading pathogen associated with nosocomial infections. It has a vast arsenal of pathogenicity factors that are used to interfere with host defenses. Pathogenesis in P. aeruginosa facilitates adhesion, modulate or disrupt host cell pathways, and target the extracellular matrix. The propensity of P. aeruginosa to form biofilms further protects it from antibiotics and the host immune system. P. aeruginosa is intrinsically resistant to a large number of antibiotics and can be acquired resistance to many others, making treatment difficult. P. aeruginosa provokes a potent inflammatory response during the infectious process. The majority of mortalities in immunocompromised patients; cystic fibrosis, can be attributed to the progressive decline of lung function resulting from chronic infection by pathogens such as P. aeruginosa . Antibiotic treatment of chronic P. aeruginosa infections may temporarily suppress symptoms; however, they do not eradicate the pathogen. Lung diseases caused by P. aeruginosa are a leading cause of death in immunocompromised individuals as well as in children. Although immunocytes recruitment is critical to augment the host defense, excessive neutrophil accumulation results in life-threatening diseases, such as acute lung injury, as well as acute respiratory distress syndrome. Several virulence factors have been studied for their roles as potential vaccine candidate, although there is currently no clinically accepted vaccine. Understanding host-pathogen interaction is critical for the development of effective therapeutic strategies to control the damage in the lung.
- 8 January 2015
- Published by Canadian Center of Science and Education in International Journal of Biology
- Vol. 7 (2) , p44
Open AccessPseudomonas aeruginosa – Pathogenesis and Pathogenic Mechanisms
Pseudomonas aeruginosa is a common bacterium, Gram-negative opportunistic pathogen capable of infecting humans with compromised natural defenses and causing severe pulmonary disease. It is one of the leading pathogen associated with nosocomial infections. It has a vast arsenal of pathogenicity factors that are used to interfere with host defenses. Pathogenesis in P. aeruginosa facilitates adhesion, modulate or disrupt host cell pathways, and target the extracellular matrix. The propensity of P. aeruginosa to form biofilms further protects it from antibiotics and the host immune system. P. aeruginosa is intrinsically resistant to a large number of antibiotics and can be acquired resistance to many others, making treatment difficult. P. aeruginosa provokes a potent inflammatory response during the infectious process. The majority of mortalities in immunocompromised patients; cystic fibrosis, can be attributed to the progressive decline of lung function resulting from chronic infection by pathogens such as P. aeruginosa . Antibiotic treatment of chronic P. aeruginosa infections may temporarily suppress symptoms; however, they do not eradicate the pathogen. Lung diseases caused by P. aeruginosa are a leading cause of death in immunocompromised individuals as well as in children. Although immunocytes recruitment is critical to augment the host defense, excessive neutrophil accumulation results in life-threatening diseases, such as acute lung injury, as well as acute respiratory distress syndrome. Several virulence factors have been studied for their roles as potential vaccine candidate, although there is currently no clinically accepted vaccine. Understanding host-pathogen interaction is critical for the development of effective therapeutic strategies to control the damage in the lung.